BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ali Khan R, Kapur P, Jain A, Farah F, Bhandari U. Effect of orlistat on periostin, adiponectin, inflammatory markers and ultrasound grades of fatty liver in obese NAFLD patients. Ther Clin Risk Manag 2017;13:139-49. [PMID: 28260907 DOI: 10.2147/TCRM.S124621] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
Number Citing Articles
1 Haghbin H, Gangwani MK, Ravi SJK, Perisetti A, Aziz M, Goyal H, Nawras A, Sodeman T. Nonalcoholic fatty liver disease and atrial fibrillation: possible pathophysiological links and therapeutic interventions. Ann Gastroenterol 2020;33:603-14. [PMID: 33162737 DOI: 10.20524/aog.2020.0550] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Akbari R, Yaghooti H, Jalali MT, Khorsandi LS, Mohammadtaghvaei N. Capparis spinosa improves the high fat diet-induced non-alcoholic steatohepatitis in rats: the possible role of FGF21. BMC Res Notes 2020;13:356. [PMID: 32723353 DOI: 10.1186/s13104-020-05200-4] [Reference Citation Analysis]
3 Crawford AR, Alamuddin N, Amaro A. Cardiometabolic Effects of Anti-obesity Pharmacotherapy. Curr Atheroscler Rep 2018;20:18. [PMID: 29511882 DOI: 10.1007/s11883-018-0719-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
4 Heydari M, Cornide-Petronio ME, Jiménez-Castro MB, Peralta C. Data on Adiponectin from 2010 to 2020: Therapeutic Target and Prognostic Factor for Liver Diseases? Int J Mol Sci 2020;21:E5242. [PMID: 32718097 DOI: 10.3390/ijms21155242] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
5 Szanto KB, Li J, Cordero P, Oben JA. Ethnic differences and heterogeneity in genetic and metabolic makeup contributing to nonalcoholic fatty liver disease. Diabetes Metab Syndr Obes. 2019;12:357-367. [PMID: 30936733 DOI: 10.2147/dmso.s182331] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
6 Zakaria Z, Othman ZA, Bagi Suleiman J, Jalil NAC, Ghazali WSW, Mohamed M. Protective and Therapeutic Effects of Orlistat on Metabolic Syndrome and Oxidative Stress in High-Fat Diet-Induced Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Rats: Role on Nrf2 Activation. Vet Sci 2021;8:274. [PMID: 34822647 DOI: 10.3390/vetsci8110274] [Reference Citation Analysis]
7 Ye J, Wu Y, Li F, Wu T, Shao C, Lin Y, Wang W, Feng S, Zhong B. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction. Therap Adv Gastroenterol 2019;12:1756284819879047. [PMID: 31632457 DOI: 10.1177/1756284819879047] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
8 Rehman K, Munawar SM, Akash MSH, Buabeid MA, Chohan TA, Tariq M, Jabeen K, Arafa EA. Hesperidin improves insulin resistance via down-regulation of inflammatory responses: Biochemical analysis and in silico validation. PLoS One 2020;15:e0227637. [PMID: 31929574 DOI: 10.1371/journal.pone.0227637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Esmail VAW, Mohammed MO, Al-Nimer MSM. Short-term orlistat therapy improves fatty infiltration indices and liver fibrosis scores in patients with non-alcoholic fatty liver disease and metabolic syndrome. Arab J Gastroenterol 2021;22:1-5. [PMID: 33664007 DOI: 10.1016/j.ajg.2020.12.005] [Reference Citation Analysis]
10 Wang H, Wang L, Cheng Y, Xia Z, Liao Y, Cao J. Efficacy of orlistat in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Biomed Rep 2018;9:90-6. [PMID: 29930810 DOI: 10.3892/br.2018.1100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]